U.s. food and drug administration grants breakthrough therapy designation to takeda's investigational compound, tak-994, an oral orexin agonist in clinical development for narcolepsy type 1 (nt1)

Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the u.s. food and drug administration (fda) granted breakthrough therapy designation (btd) to tak-994,1 its phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. tak-994 is currently being studied for the treatment of excessive daytime sleepiness (eds) in patients with narcolepsy type 1 (nt1),2 a chronic ne
TAK Ratings Summary
TAK Quant Ranking